Up a level |
Massias, JS, Smith, EMD, Al-Abadi, E, Armon, K, Bailey, K, Ciurtin, C, Davidson, J, Gardner-Medwin, J, Haslam, K, Hawley, DP et al (show 14 more authors)
(2020)
Clinical and laboratory characteristics in juvenile-onset systemic lupus erythematosus across age groups.
LUPUS, 29 (5).
pp. 474-481.
Ramanan, AV, Hampson, LV, Lythgoe, H, Jones, AP, Hardwick, B, Hind, H, Jacobs, B, Vasileiou, D, Wadsworth, I, Ambrose, N et al (show 11 more authors)
(2019)
Defining consensus opinion to develop randomised controlled trials in rare diseases using Bayesian design: An example of a proposed trial of adalimumab versus pamidronate for children with CNO/CRMO.
PLOS ONE, 14 (6).
e0215739-.
Lythgoe, H, Morgan, T, Heaf, E, Lloyd, O, Al-Abadi, E, Armon, K, Bailey, K, Davidson, J, Friswell, M, Gardner-Medwin, J et al (show 10 more authors)
(2017)
Evaluation of the ACR and SLICC classification criteria in juvenile-onset systemic lupus erythematosus: a longitudinal analysis.
LUPUS, 26 (12).
pp. 1285-1290.
Smith, Emd, Al-Abadi, E, Armon, K, Bailey, K, Ciurtin, C, Davidson, J, Gardner-Medwin, J, Haslam, K, Hawley, D, Leahy, A et al (show 13 more authors)
(2019)
Outcomes following mycophenolate mofetil versus cyclophosphamide induction treatment for proliferative juvenile-onset lupus nephritis.
Lupus, 28 (5).
p. 961203319836712.